Maraviroc/cisplatin Combination Inhibits Gastric Cancer Tumoroid Growth and Improves Mice Survival

Overview

Journal Biol Res

Date 2025 Jan 18

PMID 39827154

Authors

Barbara Mora-Lagos

Maria Elena Reyes

Lorena Lobos-Gonzalez

Matias Del Campo

Kurt Buchegger

Louise Zanella

Ismael Riquelme

Carmen Gloria Ili

Priscilla Brebi

Affiliations

Soon will be listed here.

Abstract

Background: Gastric cancer (GC) is a significant cancer-related cause of death worldwide. GC's most used chemotherapeutic regimen is based on platinum drugs such as cisplatin (CDDP). However, CDDP chemoresistance reduces the survival rate of advanced GC. The immune C-C chemokine receptor type 5 (CCR5) have been proposed as a pivotal factor in cancer progression since its blockade has been linked with antineoplastic effects on tumor cell proliferation; nevertheless, its role in the chemoresistance of GC has not been elucidated. This study aimed to determine the effects induced by the CCR5 using Maraviroc (MVC), a highly selective CCR5 antagonist, on CDDP-resistant AGS cells (AGS R-CDDP), tumoroids (3D tumor spheroids), and animal models.

Results: The combined CDDP and MVC treatment reduced cell viability and inhibited tumoroid formation in AGS R-CDDP cells. The effects of the MVC/CDDP combination on apoptosis and cell cycle progression were correlated with the increase in CDDP (dose-dependent). The mRNA levels of C-C Motif Chemokine Ligand 5 (CCL5), the main ligand for CCR5, decreased significantly in cells treated with the MVC/CDDP combination. MVC in the MVC/CDDP combination improved the survival rate and biochemical parameters of CDDP-treated mice by reducing the side effects of CDDP alone.

Conclusions: This finding suggests that MVC/CDDP combination could be a potential complementary therapy for GC.

References

Abbasi-Malati Z, Khanicheragh P, Narmi M, Mardi N, Khosrowshahi N, Hiradfar A . Tumoroids, a valid preclinical screening platform for monitoring cancer angiogenesis. Stem Cell Res Ther. 2024; 15(1):267. PMC: 11346257. DOI: 10.1186/s13287-024-03880-4. View

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

Li L, Guan Y, Chen X, Yang J, Cheng Y . DNA Repair Pathways in Cancer Therapy and Resistance. Front Pharmacol. 2021; 11:629266. PMC: 7898236. DOI: 10.3389/fphar.2020.629266. View

Singh S, Mishra M, Rivers B, Gordetsky J, Bae S, Singh R . Biological and Clinical Significance of the CCR5/CCL5 Axis in Hepatocellular Carcinoma. Cancers (Basel). 2020; 12(4). PMC: 7226629. DOI: 10.3390/cancers12040883. View

Lobos-Gonzalez L, Aguilar-Guzman L, Fernandez J, Munoz N, Hossain M, Bieneck S . Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models. Melanoma Res. 2014; 24(2):108-19. PMC: 3999137. DOI: 10.1097/CMR.0000000000000046. View

Yang T, Chen M, Yang X, Zhang X, Zhang Z, Sun Y . Down-regulation of KLF5 in cancer-associated fibroblasts inhibit gastric cancer cells progression by CCL5/CCR5 axis. Cancer Biol Ther. 2017; 18(10):806-815. PMC: 5678703. DOI: 10.1080/15384047.2017.1373219. View

Reyes M, De la Fuente M, Hermoso M, Ili C, Brebi P . Role of CC Chemokines Subfamily in the Platinum Drugs Resistance Promotion in Cancer. Front Immunol. 2020; 11:901. PMC: 7243460. DOI: 10.3389/fimmu.2020.00901. View

Yip H, Chopra R, Chakrabarti R, Veena M, Ramamurthy B, Srivatsan E . Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53. Arch Otolaryngol Head Neck Surg. 2006; 132(3):317-26. DOI: 10.1001/archotol.132.3.317. View

DiNatale A, Kaur R, Qian C, Zhang J, Marchioli M, Ipe D . Subsets of cancer cells expressing CX3CR1 are endowed with metastasis-initiating properties and resistance to chemotherapy. Oncogene. 2022; 41(9):1337-1351. PMC: 8941631. DOI: 10.1038/s41388-021-02174-w. View

10.

Li C, Qiu J, Xue Y . Low-dose Diosbulbin-B (DB) activates tumor-intrinsic PD-L1/NLRP3 signaling pathway mediated pyroptotic cell death to increase cisplatin-sensitivity in gastric cancer (GC). Cell Biosci. 2021; 11(1):38. PMC: 7881658. DOI: 10.1186/s13578-021-00548-x. View

11.

Mencarelli A, Graziosi L, Renga B, Cipriani S, DAmore C, Francisci D . CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. Transl Oncol. 2014; 6(6):784-93. PMC: 3890714. DOI: 10.1593/tlo.13499. View

12.

Cambien B, Richard-Fiardo P, Karimdjee B, Martini V, Ferrua B, Pitard B . CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma. PLoS One. 2011; 6(12):e28842. PMC: 3243667. DOI: 10.1371/journal.pone.0028842. View

13.

Ryu H, Baek S, Moon J, Jo I, Kim N, Lee H . C-C motif chemokine receptors in gastric cancer. Mol Clin Oncol. 2017; 8(1):3-8. PMC: 5738695. DOI: 10.3892/mco.2017.1470. View

14.

Lobos-Gonzalez L, Aguilar L, Diaz J, Diaz N, Urra H, Torres V . E-cadherin determines Caveolin-1 tumor suppression or metastasis enhancing function in melanoma cells. Pigment Cell Melanoma Res. 2013; 26(4):555-70. PMC: 3695072. DOI: 10.1111/pcmr.12085. View

15.

Rocha C, Silva M, Quinet A, Cabral-Neto J, Menck C . DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics (Sao Paulo). 2018; 73(suppl 1):e478s. PMC: 6113849. DOI: 10.6061/clinics/2018/e478s. View

16.

Singh S, Mishra M, Eltoum I, Bae S, Lillard Jr J, Singh R . CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci Rep. 2018; 8(1):1323. PMC: 5778036. DOI: 10.1038/s41598-018-19643-0. View

17.

Velasco-Velazquez M, Jiao X, De La Fuente M, Pestell T, Ertel A, Lisanti M . CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012; 72(15):3839-50. DOI: 10.1158/0008-5472.CAN-11-3917. View

18.

Mora-Lagos B, Cartas-Espinel I, Riquelme I, Parker A, Piccolo S, Viscarra T . Functional and transcriptomic characterization of cisplatin-resistant AGS and MKN-28 gastric cancer cell lines. PLoS One. 2020; 15(1):e0228331. PMC: 6986722. DOI: 10.1371/journal.pone.0228331. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Shi W, Gao J . Molecular mechanisms of chemoresistance in gastric cancer. World J Gastrointest Oncol. 2016; 8(9):673-81. PMC: 5027022. DOI: 10.4251/wjgo.v8.i9.673. View